Form 4: COMPASS Pathways Director Annalisa Jenkins Granted 26,000 Stock Options

COMPASS Pathways plc Director Annalisa Jenkins has been granted 26,000 share options at an exercise price of $4.52, aligning her interests with shareholders.

Summary

• Annalisa Jenkins, a Director of COMPASS Pathways plc (CMPS), was granted 26,000 share options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these options is $4.52 per share.
• The options will vest in full upon the earlier of the first anniversary of the grant date (June 12, 2026) or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.
• The options have an expiration date of June 11, 2035.
• The underlying securities are Ordinary Shares, which may be represented by American Depositary Shares (ADSs), with each ADS currently representing one Ordinary Share.
• Following this transaction, Annalisa Jenkins beneficially owns 26,000 derivative securities (share options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is a routine disclosure and not indicative of significant operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the company's shareholders, incentivizing long-term performance and value creation.
• The exercise price of $4.52 provides a clear benchmark for future share price performance relative to the grant.

Future Outlook

The granted options are subject to a vesting schedule, indicating that the director's full beneficial ownership of the underlying shares is contingent upon continued service until at least June 2026 or the 2026 Annual General Meeting, aligning future incentives.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a key component of executive and director compensation packages to attract and retain talent and align their interests with long-term company performance.

Comparison to Industry Standards

• Stock option grants are a standard form of non-cash compensation for directors in publicly traded companies, particularly in growth-oriented sectors like biotechnology, where long-term value creation is emphasized.
• The vesting schedule, tied to either a specific anniversary or the Annual General Meeting, is a typical mechanism to ensure continued commitment and performance from board members.
• While specific comparable companies or projects are not detailed in this filing, the structure of this compensation aligns with general corporate governance practices for director remuneration in the U.S. market.

Corporate Governance

Related Party Transactions

• The grant of 26,000 share options to Annalisa Jenkins, a Director of COMPASS Pathways plc, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: While not directly impacting employees, such compensation practices for leadership can set a precedent for performance-based incentives across the organization.

Next Steps

• The options will vest in full upon the earlier of June 12, 2026, or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 11, 2035.

Key Dates

Keywords

COMPASS Pathways, CMPS, SEC Form 4, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Pharmaceutical, Biotechnology